Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6194802rdf:typepubmed:Citationlld:pubmed
pubmed-article:6194802lifeskim:mentionsumls-concept:C2349001lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0006309lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0681850lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C1706203lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C2697811lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0022230lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0022877lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C1550501lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0549193lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0443172lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:6194802lifeskim:mentionsumls-concept:C1527392lld:lifeskim
pubmed-article:6194802pubmed:issue7lld:pubmed
pubmed-article:6194802pubmed:dateCreated1983-12-17lld:pubmed
pubmed-article:6194802pubmed:abstractTextIn order to evaluate the immunomodulating activity of isoprinosine in chronic infections, 7 patients with chronic brucellosis unresponsive to antibiotic and corticosteroid therapy were treated with 4 g/die of isoprinosine in association with antibiotic therapy from 3 to 6 months. Immunoserologic and clinical evaluation were obtained at regular intervals from each patient. The treatment induced a significant increase of E rosette formation, reduction of erythrocyte sedimentation rate, associated with improvement or disappearance of clinical symptoms. These data suggest that isoprinosine may favourably influence the clinical course of chronic brucellosis, probably modifying host cell-mediated immune response.lld:pubmed
pubmed-article:6194802pubmed:languageitalld:pubmed
pubmed-article:6194802pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6194802pubmed:citationSubsetIMlld:pubmed
pubmed-article:6194802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6194802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6194802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6194802pubmed:statusMEDLINElld:pubmed
pubmed-article:6194802pubmed:monthJullld:pubmed
pubmed-article:6194802pubmed:issn0037-8771lld:pubmed
pubmed-article:6194802pubmed:authorpubmed-author:SchiraldiOOlld:pubmed
pubmed-article:6194802pubmed:authorpubmed-author:FeraGGlld:pubmed
pubmed-article:6194802pubmed:authorpubmed-author:FrappampinaVVlld:pubmed
pubmed-article:6194802pubmed:authorpubmed-author:BaldePPlld:pubmed
pubmed-article:6194802pubmed:issnTypePrintlld:pubmed
pubmed-article:6194802pubmed:day30lld:pubmed
pubmed-article:6194802pubmed:volume59lld:pubmed
pubmed-article:6194802pubmed:ownerNLMlld:pubmed
pubmed-article:6194802pubmed:authorsCompleteYlld:pubmed
pubmed-article:6194802pubmed:pagination909-13lld:pubmed
pubmed-article:6194802pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6194802pubmed:meshHeadingpubmed-meshheading:6194802-...lld:pubmed
pubmed-article:6194802pubmed:meshHeadingpubmed-meshheading:6194802-...lld:pubmed
pubmed-article:6194802pubmed:meshHeadingpubmed-meshheading:6194802-...lld:pubmed
pubmed-article:6194802pubmed:meshHeadingpubmed-meshheading:6194802-...lld:pubmed
pubmed-article:6194802pubmed:meshHeadingpubmed-meshheading:6194802-...lld:pubmed
pubmed-article:6194802pubmed:meshHeadingpubmed-meshheading:6194802-...lld:pubmed
pubmed-article:6194802pubmed:meshHeadingpubmed-meshheading:6194802-...lld:pubmed
pubmed-article:6194802pubmed:meshHeadingpubmed-meshheading:6194802-...lld:pubmed
pubmed-article:6194802pubmed:meshHeadingpubmed-meshheading:6194802-...lld:pubmed
pubmed-article:6194802pubmed:year1983lld:pubmed
pubmed-article:6194802pubmed:articleTitle[Changes in laboratory and clinical parameters in subjects with chronic brucellosis treated with an immunomodulator: methisoprinol].lld:pubmed
pubmed-article:6194802pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6194802pubmed:publicationTypeEnglish Abstractlld:pubmed